United Therapeutics Co. (NASDAQ:UTHR) Director Christopher Causey sold 810 shares of the firm’s stock in a transaction dated Thursday, September 6th. The shares were sold at an average price of $118.00, for a total value of $95,580.00. Following the transaction, the director now directly owns 3,925 shares in the company, valued at $463,150. The sale was disclosed in a document filed with the SEC, which is available at this link.
United Therapeutics stock traded up $0.05 during trading hours on Friday, reaching $118.48. The company had a trading volume of 203,100 shares, compared to its average volume of 389,776. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.64 and a quick ratio of 4.35. The stock has a market capitalization of $5.19 billion, a P/E ratio of 10.78, a price-to-earnings-growth ratio of 26.91 and a beta of 1.24. United Therapeutics Co. has a 12-month low of $100.57 and a 12-month high of $152.55.
United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, August 1st. The biotechnology company reported $3.98 EPS for the quarter, topping the Zacks’ consensus estimate of $2.57 by $1.41. The business had revenue of $444.50 million for the quarter, compared to analysts’ expectations of $368.63 million. United Therapeutics had a return on equity of 34.42% and a net margin of 40.87%. The business’s quarterly revenue was up .0% on a year-over-year basis. During the same period in the previous year, the firm earned $4.37 EPS. sell-side analysts expect that United Therapeutics Co. will post 14.77 earnings per share for the current fiscal year.
A number of institutional investors have recently made changes to their positions in UTHR. Legacy Financial Advisors Inc. purchased a new position in United Therapeutics in the 2nd quarter worth approximately $107,000. Sun Life Financial INC purchased a new position in shares of United Therapeutics during the second quarter valued at approximately $198,000. HL Financial Services LLC increased its stake in shares of United Therapeutics by 40.2% during the first quarter. HL Financial Services LLC now owns 2,053 shares of the biotechnology company’s stock valued at $231,000 after buying an additional 589 shares during the period. Trexquant Investment LP purchased a new position in shares of United Therapeutics during the first quarter valued at approximately $266,000. Finally, Fox Run Management L.L.C. purchased a new position in shares of United Therapeutics during the second quarter valued at approximately $269,000. 95.86% of the stock is currently owned by institutional investors and hedge funds.
A number of equities analysts recently weighed in on UTHR shares. TheStreet raised United Therapeutics from a “c+” rating to a “b” rating in a report on Thursday, August 16th. BidaskClub raised United Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, July 11th. Zacks Investment Research raised United Therapeutics from a “hold” rating to a “buy” rating and set a $127.00 price objective on the stock in a report on Saturday, July 7th. Wedbush set a $253.00 price target on United Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, August 8th. Finally, HC Wainwright set a $95.00 price target on United Therapeutics and gave the stock a “hold” rating in a research note on Monday, August 13th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the company. United Therapeutics currently has an average rating of “Hold” and an average price target of $138.86.
About United Therapeutics
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Further Reading: Return on Investment (ROI)
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.